Business

CannTen expands portfolio with six CBD presentations

CannTen expands its portfolio in Brazil following Anvisa's authorization for three cannabidiol concentrations across six distinct commercial presentations. Read more.

CannTen expands portfolio with six CBD presentations
CannTen expands its medicinal cannabis product portfolio following new sanitary authorizations from Anvisa.

CannTen has received sanitary authorization from the Brazilian Health Regulatory Agency (Anvisa) for three new concentrations of isolated cannabidiol (CBD)-based products: 50 mg/mL, 100 mg/mL, and 150 mg/mL. The authorizations cover six commercial presentations, distributed in 10 mL and 30 mL bottles, expanding the company's portfolio in the Brazilian medicinal cannabis market.

The approval was published in the Official Gazette of the Union (DOU) on November 9, 2026, via Resolution-RE No. 4,396, dated November 6. The official document identifies three products, each with two commercial presentations, totaling six presentation registrations.

Read also: 

With the new authorization, the company now offers different concentrations of isolated cannabidiol, providing dosage and packaging volume options to healthcare professionals working with cannabis-based therapies.

In a press release, CannTen highlighted that the expansion is part of its growth strategy and commitment to strengthening operations in Brazil. The company also emphasized that it works with products sourced internationally, particularly from Europe and Latin America.

CannTen bets on diversifying its Brazilian portfolio

0d17fe11-01b0-4592-a5aa-7e71410dd767.webp
Ori Alperovitz, CEO of CannTen.

For Ori Alperovitz, CEO of CannTen, the approval marks a step forward in the company's growth strategy in the country and reinforces its long-term commitment to the Brazilian market.

"We are extremely pleased and proud of this significant regulatory achievement. The approval of six new medicinal cannabis products, in isolated cannabidiol presentations, represents a major milestone in CannTen's development and reinforces our long-term commitment to the Brazilian market," said the executive.

Alperovitz also emphasized that the company's strategy involves broadening its footprint in the country by bringing in products developed across different international markets.

"Our strategy is to continue expanding our presence and capabilities in Brazil, bringing new products from diverse origins in Europe and Latin America," he stated.

Portfolio diversification is presented by the company as a way to expand therapeutic alternatives available to healthcare providers. According to CannTen, the variety of concentrations and formats allows physicians and dental surgeons to evaluate different product options according to the individual needs of each patient.

Company highlights potential for personalized treatments

Another point addressed by the CEO is the relationship between product diversity and the individualization of medicinal cannabis treatments.

"We believe that a broader and more diversified portfolio provides healthcare professionals with a greater therapeutic arsenal capable of customizing treatments according to each patient's needs, enabling the selection of the most suitable product and dosage for each therapeutic indication," Alperovitz stated.

The statement reflects the company's perspective on expanding its portfolio. The availability of different concentrations, however, does not constitute proven efficacy for new therapeutic indications. Determining treatment must take into account each patient's individual assessment and the guidance of the attending professional.

Commenting on the company's next steps, the executive reaffirmed the goal of expanding operations in the country and increasing the availability of products from various origins.

"Our goal is to continue strengthening CannTen's position in Brazil and broaden Brazilian patients' access to an increasingly diverse portfolio of quality medicinal cannabis products," he concluded.

What did Anvisa authorize for CannTen?

Resolution-RE No. 4,396/2026 outlines three cannabidiol products from the company, all classified under the cannabis products category with a THC concentration of up to 0.2%.

The authorized concentrations and presentations are:

  • Canabidiol CannTen 50 mg/mL: 10 mL and 30 mL bottles, with a 24-month shelf life.
  • Canabidiol CannTen 100 mg/mL: 10 mL and 30 mL bottles, with a 24-month shelf life.
  • Canabidiol CannTen 150 mg/mL: 10 mL and 30 mL bottles, with a 24-month shelf life.

All three sanitary authorizations are scheduled to expire in November 2031.